Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Paxil OS GMP Concerns Resolved By Year-End, GSK Says After Warning Letter

  • News

Executive Summary

GlaxoSmithKline expects to resolve GMP issues related to production of Paxil oral suspension at its Certenejas Cidra, Puerto Rico facility by the end of the month, the company said

You may also be interested in...



GSK Puerto Rico Plant Under Investigation By FDA; Received Warning In 2002

GlaxoSmithKline does not anticipate any immediate supply disruptions from an FDA investigation of its Cidra, Puerto Rico production facility

GSK Puerto Rico Plant Under Investigation By FDA; Received Warning In 2002

GlaxoSmithKline does not anticipate any immediate supply disruptions from an FDA investigation of its Cidra, Puerto Rico production facility

GSK Manufacturing Consolidation Has Helped GMP Compliance, Firm Says

GlaxoSmithKline's manufacturing streamlining has helped the company avoid trouble during the recent round of FDA good manufacturing practices enforcement, CEO J.P. Garnier told investors Oct. 23

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

See All
UsernamePublicRestriction

Register

PS040917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By